Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients, and a substantial number of patients are being treated with oral anticoagulants. We aim to assess the comparative effectiveness of direct oral anticoagulants (DOACs) compared to warfarin for VTE treatment in cancer patients.
Methods: In this retrospective cohort study, we included 2,367 cancer patients who are new users of oral anticoagulants (OACs) for VTE treatment from 2009 to 2021 in NHS Scotland. Patients were grouped by OAC type, DOACs or warfarin. To adjust for confounding, inverse probability treatment weighting was applied. Outcomes included mortality, VTE recurrence, and major bleeding. We calculated Hazard Ratio (HR) using Cox regression and sub-distribution HR (sHR) using a competing risk framework (Fine and Gray method) for VTE recurrence and major bleeding. Subgroup analyses were conducted for individual DOACs.
Results: Patients on DOACs had lower risks of VTE recurrence (sHR 0.73 95% CI 0.59-0.90) and major bleeding (sHR 0.68, 95% CI 0.53-0.88) compared to patients on warfarin. Patients on rivaroxaban (HR 1.21, 95% CI 1.04-1.39) and edoxaban (HR 1.59, 95% CI 1.15-2.22) had a significantly higher risk of mortality, while a comparable risk of mortality was observed (HR 0.91, 95% CI 0.76-1.08) for patients on apixaban compared to patients on warfarin.
Conclusion: This study provides insight into the effectiveness of DOACs compared to warfarin for VTE in cancer patients. Patients on DOACs had lower risks of VTE recurrence and major bleeding. We suggest healthcare professionals consider the potential benefits of individual DOACs when making treatment decisions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cam4.71209 | DOI Listing |
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418083 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Perioperative Anticoagulation Management: Revisiting Bridging Strategies for Mechanical and Nonmechanical Indications.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Patients with atrial fibrillation, venous thrombosis, and mechanical heart valve (MHV) regularly undergo procedures on a daily basis, for which they require bridging anticoagulation, but this poses significant challenges. Bridging anticoagulation involves temporary interruption of long-term anticoagulation therapy for procedures and continued overlap with short-acting anticoagulants during perioperative period. Heparin-based agents are often used for overlapping in perioperative period to reduce the risk of thromboembolism, but the evidence for benefit particularly in patients with MHV remains limited.
View Article and Find Full Text PDFWarfarin reduces circulating white blood cell count: Post-hoc analysis of two randomized trials.
Thromb Res
September 2025
Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Electronic address:
Warfarin is a widely used vitamin K antagonist (VKA) with known pleiotropic effects beyond anticoagulation. Preclinical and case-control evidence suggests that warfarin may affect hematopoiesis, but longitudinal human evidence is lacking. To explore this potential effect, we conducted a post-hoc analysis of participants in the Hokusai-VTE and ENGAGE AF-TIMI 48 trials, which randomized patients to warfarin or the direct oral anticoagulant edoxaban with routine laboratory testing at predefined follow-up visits.
View Article and Find Full Text PDFLeft Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation.
JAMA Netw Open
September 2025
Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock.
Importance: Patients with kidney failure (KF) receiving long-term dialysis have increased incidence of atrial fibrillation (AF). Patients with KF and AF have increased risk of stroke, death, and bleeding compared with age-matched cohorts. In KF, the use of oral anticoagulants (OACs) increases hemorrhage risk, offsetting potential benefits and making left atrial appendage occlusion (LAAO) a potentially promising solution for risk reduction in AF.
View Article and Find Full Text PDFPotential clinical benefits of proton pump inhibitors for secondary prevention of recurrent bleeding among patients with upper gastrointestinal bleeding receiving oral anticoagulants: a systematic review and meta-analysis.
Int J Pharm Pract
September 2025
Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Suthep Road, Suthep, Mueang, Chiang Mai 50200, Thailand.
Objectives: Proton pump inhibitors (PPIs) are commonly used among these patients to prevent upper gastrointestinal bleeding (UGIB) in anticoagulated patients. However, their clinical benefits among patients receiving OACs with a history of UGIB remain inconclusive. This study aimed to summarize the clinical benefits of PPIs for the secondary prevention of recurrent UGIB among patients using OACs.
View Article and Find Full Text PDFComparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients.
Cancer Med
September 2025
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
Introduction: Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients, and a substantial number of patients are being treated with oral anticoagulants. We aim to assess the comparative effectiveness of direct oral anticoagulants (DOACs) compared to warfarin for VTE treatment in cancer patients.
Methods: In this retrospective cohort study, we included 2,367 cancer patients who are new users of oral anticoagulants (OACs) for VTE treatment from 2009 to 2021 in NHS Scotland.